65岁以上的老年人使用普坦和因严重血管事件而入院的风险
Phuong Thao Tran1,2, Maryse Lapeyre-Mestre1,3, Baricault Berangere1,3
1Service de Pharmacologie Médicale et Clinique, Université de Toulouse, CHU de Toulouse, Toulouse, France.
The journal of headache and pain
|April 26, 2024
概括
老年人使用普坦可能会略微增加急性血管事件的风险,特别是诸如中风之类的脑事件. 在这个人群中,这些事件的总体发病率仍然很低.
科学领域:
- 心血管疾病流行病学
- 药物监督 药物监督 药物监督
- 老年医学 老年医学
背景情况:
- 关于三胺使用与急性血管事件之间的关联仍在争论中,特别是在65岁以上的人群中.
- 之前的研究没有量化老年人群中这种风险.
研究的目的:
- 评估65岁及以上患者因急性血管事件住院治疗的风险.
主要方法:
- 一项倾向分数匹配的队列研究使用了法国国家医疗保险数据.
- 包括年龄≥65岁的新接受三药治疗的患者 (2011-2014).
- 主要结局:急性缺血性血管事件住院治疗90天内. 使用考克斯回归,病例交叉 (CCO) 和自我控制病例系列 (SCCS) 模型进行分析.
主要成果:
- 该研究包括24774名三胺使用者和99096名对照人群 (平均年龄71岁).
- 观察到血管事件的发病率较低 (0.66%对0.53%).
- 三类药物的使用与风险增加有关 (aHR 1.25 [1.05-1.49]),在CCO (aOR 1.63 [1.22-2.19]) 和SCCS (RI 2.13 [1.76-2.58]) 分析中发现了显著的发现,特别是在大脑事件中.
结论:
- 在老年人中,使用普坦与急性血管事件风险的小幅增加有关.
- 这种风险在脑部事件 (如中风) 中显得更明显,而不是心脏事件.
- 在这个患者群体中,急性血管事件的总体发病率仍然很低.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
377
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
377
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
496
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antihypertensive Drugs: Vasodilators
513
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
513
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337


